Linkedin Twitter
Contact

Collaborate with Us

All you need is an antibody. We have everything else.

Technology evaluation is fast and easy

We actively embrace research collaborations with companies who look towards external innovation to build their pipelines.

Because we do not modify your antibody sequence to deliver best-in-class ADCs or bispecifics, it means you can move very quickly into proof-of-concept studies and product development.

Typical Work Flow

  1. Antibody shipped to Synaffix
  2. Synaffix prepares ADCs and/or bispecifics
  3. Characterized conjugates shipped back to collaborator
  4. Collaborator generates in vivo POC data
  5. Technology Licensing Go/No Go 

Let's
work
together

Send us an email

Just drop us your info

Protein Conjugates

Bring your own and/or choose from the following categories. 

 

Just like our ADC technology, we can easily attach peptide and protein-based payloads to your antibody.

 

Early preclinical data available on request.

Bring Your Own

scFv / Fab
Cytokine

Immune Cell Recruiters

Anti-CD3

T cell recruitment
IL-15

NK cell recruitment

IL-15 Receptor Fusion

NK cell recruitment

HydraSpace™ Polar Spacer

Forming an integral part of every toxSYN™ linker-payload, HydraSpace™ bears a negative charge at physiological pH and improves:

  1. Therapeutic efficacy
  2. Tolerability
  3. PK
  4. Manufacturability
Key publication about HydraSpace
HydraSpace™

GlycoConnect™ design easily matches payload potency with the most appropriate drug-antibody ratio (DAR).

Key publications about GlycoConnect™

GlycoConnect™ ADCs
Metal-Free Click Conjugation
Enzymatic ADCs (Review)
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1

toxSYN™ Linker-Payloads

Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
DAR1 Drug Antibody Ratio 1:1
DAR1
Drug Antibody Ratio 1:1
DAR4 Drug Antibody Ratio 4:1
DAR4
Drug Antibody Ratio 4:1
DAR2 Drug Antibody Ratio 2:1
DAR2
Drug Antibody Ratio 2:1
toxSYN™
Linker-Payload		 Mode-of-Action Payload
(Active Catabolite)
1. SYNtecan E™*Topoisomerase 1 inhibitor Camptothecin-based
2. SYNeamicin D™*DNA
damaging agent		 Calicheamicin-based
3. SYNeamicin G™*
4. SYN-PNU™*Nemorubicin-based
5. SYNstatin E™Microtubule
inhibitors		 Auristatin-based
6. SYNstatin F™
7. SYNtansine™ Maytansine-based

* Patent protection filed by Synaffix, beyond the claims of GlycoConnect™ and HydraSpace™

** N-6-aminohexanoyl-maytansine (Ahx-maytansine)